Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer

Genome Medicine

Volumn 4, Issue 4, 2012, Pages

  Ament, Zsuzsanna ^a,b   Masoodi, Mojgan ^a,b   Griffin, Julian L ^a,b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Functional genomics; Metabolic syndrome; Obesity; Peroxisome proliferator activated receptors; The metabolic syndrome; Type II diabetes

Indexed keywords

ALEGLITAZAR; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TESAGLITAZAR; TROGLITAZONE;

ADIPOSE TISSUE; AGING; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG TARGETING; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCONEOGENESIS; HUMAN; LIPIDOMICS; METABOLOMICS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; XENOBIOTIC METABOLISM;

EID: 84860469666     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm331     Document Type: Review

References (74)

1. Evans RM, Barish GD, Wang Y-X. PPARs and the complex journey to obesity. Nat Med 2004, 10:355-361. 10.1038/nm1025, 15057233.
2. Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012, 12:181-195.
3. Delaney J, Hodson MP, Thakkar H, Connor SC, Sweatman BC, Kenny SP, McGill PJ, Holder JC, Hutton KA, Haselden JN, Waterfield CJ. Tryptophan?NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation. Arch Toxicol 2004, 79:208-223.
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471. 10.1056/NEJMoa072761, 17517853.
5. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010, 121:1868-1877. 10.1161/CIR.0b013e3181d34114, 20179252.
6. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost J-P, Le Net J-L, Baker D, Walley RJ, Everett JR, Nicholson JK. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006, 440:1073-1077. 10.1038/nature04648, 16625200.
7. Kirschenlohr HL, Griffin JL, Clarke SC, Rhydwen R, Grace AA, Schofield PM, Brindle KM, Metcalfe JC. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med 2006, 12:705-710. 10.1038/nm1432, 16732278.
8. Salek RM, Maguire ML, Bentley E, Rubtsov DV, Hough T, Cheeseman M, Nunez D, Sweatman BC, Haselden JN, Cox RD, Connor SC, Griffin JL. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genomics 2007, 29:99-108.
9. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med 2011, 17:448-453. 10.1038/nm.2307, 3126616, 21423183.
10. Kettunen J, Tukiainen T, Sarin A-P, Ortega-Alonso A, Tikkanen E, Lyytikäinen L-P, Kangas AJ, Soininen P, Würtz P, Silander K, Dick DM, Rose RJ, Savolainen MJ, Viikari J, Kähönen M, Lehtimäki T, Pietiläinen KH, Inouye M, McCarthy MI, Jula A, Eriksson J, Raitakari OT, Salomaa V, Kaprio J, Järvelin MR, Peltonen L, Perola M, Freimer NB, Ala-Korpela M, Palotie A, et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012, 44:269-276. 10.1038/ng.1073, 22286219.
11. King RD, Whelan KE, Jones FM, Reiser PGK, Bryant CH, Muggleton SH, Kell DB, Oliver SG. Functional genomic hypothesis generation and experimentation by a robot scientist. Nature 2004, 427:247-252. 10.1038/nature02236, 14724639.
12. Griffin JL, Bonney SA, Mann C, Hebbachi AM, Gibbons GF, Nicholson JK, Shoulders CC, Scott J. An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver. Physiol Genomics 2004, 17:140-149. 10.1152/physiolgenomics.00158.2003, 14747661.
13. Griffin JL, Williams HJ, Sang E, Clarke K, Rae C, Nicholson JK. Metabolic profiling of genetic disorders: a multitissue (1)H nuclear magnetic resonance spectroscopic and pattern recognition study into dystrophic tissue. Anal Biochem 2001, 293:16-21. 10.1006/abio.2001.5096, 11373073.
14. Dumas M-E, Wilder SP, Bihoreau M-T, Barton RH, Fearnside JF, Argoud K, D'Amato L, Wallis RH, Blancher C, Keun HC, Baunsgaard D, Scott J, Sidelmann UG, Nicholson JK, Gauguier D. Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models. Nat Genet 2007, 39:666-672. 10.1038/ng2026, 17435758.
15. Illig T, Gieger C, Zhai G, Römisch-Margl W, Wang-Sattler R, Prehn C, Altmaier E, Kastenmüller G, Kato BS, Mewes H-W, Meitinger T, de Angelis MH, Kronenberg F, Soranzo N, Wichmann HE, Spector TD, Adamski J, Suhre K. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2009, 42:137-141.
16. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-650. 10.1038/347645a0, 2129546.
17. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995, 15:3012-3022. 230532, 7539101.
18. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest 1999, 103:1489-1498. 10.1172/JCI6223, 408372, 10359558.
19. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999, 96:7473-7478. 10.1073/pnas.96.13.7473, 22110, 10377439.
20. Vidal-Puig A, Jimenez-Liñan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996, 97:2553-2561. 10.1172/JCI118703, 507341, 8647948.
21. Fajas L, Auboeuf D, Raspé E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997, 272:18779-18789. 10.1074/jbc.272.30.18779, 9228052.
22. Kadowaki T, Hara K, Kubota N, Tobe K, Terauchi Y, Yamauchi T, Eto K, Kadowaki H, Noda M, Hagura R, Akanuma Y. The role of PPARgamma in high-fat diet-induced obesity and insulin resistance. J Diabetes Complications 2002, 16:41-45. 10.1016/S1056-8727(01)00206-9, 11872365.
23. Medina-Gomez G, Virtue S, Lelliott C, Boiani R, Campbell M, Christodoulides C, Perrin C, Jimenez-Linan M, Blount M, Dixon J, Zahn D, Thresher RR, Aparicio S, Carlton M, Colledge WH, Kettunen MI, Seppänen-Laakso T, Sethi JK, O'Rahilly S, Brindle K, Cinti S, Oresic M, Burcelin R, Vidal-Puig A. The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. Diabetes 2005, 54:1706-1716. 10.2337/diabetes.54.6.1706, 15919792.
24. Takahashi S, Tanaka T, Kodama T, Sakai J. Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome. Pharmacol Res 2006, 53:501-507. 10.1016/j.phrs.2006.03.019, 16713711.
25. Wang Y-X, Zhang C-L, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004, 2:e294-e294. 10.1371/journal.pbio.0020294, 509410, 15328533.
26. Lee C-H, Olson P, Hevener A, Mehl I, Chong L-W, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006, 103:3444-3449. 10.1073/pnas.0511253103, 1413918, 16492734.
27. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O'Rahilly S. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003, 52:910-917. 10.2337/diabetes.52.4.910, 12663460.
28. Xu J, Xiao G, Trujillo C, Chang V, Blanco L, Joseph SB, Bassilian S, Saad MF, Tontonoz P, Lee WNP, Kurland IJ. Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production. J Biol Chem 2002, 277:50237-50244. 10.1074/jbc.M201208200, 12176975.
29. Xu J, Chang V, Joseph SB, Trujillo C, Bassilian S, Saad MF, Lee WNP, Kurland IJ. Peroxisomal proliferator-activated receptor alpha deficiency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle flux. Endocrinology 2004, 145:1087-1095.
30. Atherton HJ, Bailey NJ, Zhang W, Taylor J, Major H, Shockcor J, Clarke K, Griffin JL. A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-{alpha} null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol Genomics 2006, 27:178-186. 10.1152/physiolgenomics.00060.2006, 16868074.
31. Knauf C, Rieusset J, Foretz M, Cani PD, Uldry M, Hosokawa M, Martinez E, Bringart M, Waget A, Kersten S, Desvergne B, Gremlich S, Wahli W, Seydoux J, Delzenne NM, Thorens B, Burcelin R. Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: role in liver and brain. Endocrinology 2006, 147:4067-4078. 10.1210/en.2005-1536, 16777972.
32. Atherton HJ, Gulston MK, Bailey NJ, Cheng K-K, Zhang W, Clarke K, Griffin JL. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse. Mol Syst Biol 2009, 5:259-259. 2683722, 19357638.
33. Zhen Y, Krausz KW, Chen C, Idle JR, Gonzalez FJ. Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol Endocrinol 2007, 21:2136-2151. 10.1210/me.2007-0150, 2084472, 17550978.
34. Patterson AD, Slanar O, Krausz KW, Li F, Höfer CC, Perlík F, Gonzalez FJ, Idle JR. Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation. J Proteome Res 2009, 8:4293-4300. 10.1021/pr9004103, 2760252, 19569716.
35. Wang T, Shah YM, Matsubara T, Zhen Y, Tanabe T, Nagano T, Fotso S, Krausz KW, Zabriskie TM, Idle JR, Gonzalez FJ. Control of steroid 21-oic acid synthesis by peroxisome proliferator-activated receptor alpha and role of the hypothalamic-pituitary-adrenal axis. J Biol Chem 2010, 285:7670-7685. 10.1074/jbc.M109.090175, 2844213, 20032461.
36. Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, Ryals JA, Beebe KD, Guo L. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol 2009, 37:521-535. 10.1177/0192623309336152, 19458390.
37. Manna SK, Patterson AD, Yang Q, Krausz KW, Li H, Idle JR, Fornace AJ, Gonzalez FJ. Identification of noninvasive biomarkers for alcohol-induced liver disease using urinary metabolomics and the Ppara-null mouse. J Proteome Res 2010, 9:4176-4188. 10.1021/pr100452b, 2917755, 20540569.
38. Watkins SM, Reifsnyder PR, Pan H-J, German JB, Leiter EH. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 2002, 43:1809-1817. 10.1194/jlr.M200169-JLR200, 12401879.
39. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, Yeo GS, Lopez M, Seppänen-Laakso T, Ashcroft FM, Oresic M, Vidal-Puig A. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 2007, 3:e64-e64. 10.1371/journal.pgen.0030064, 1857730, 17465682.
40. Medina-Gomez G, Yetukuri L, Velagapudi V, Campbell M, Blount M, Jimenez-Linan M, Ros M, Oresic M, Vidal-Puig A. Adaptation and failure of pancreatic beta cells in murine models with different degrees of metabolic syndrome. Dis Model Mech 2009, 2:582-592. 10.1242/dmm.003251, 2773727, 19841237.
41. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL. Increased hepatic oxidative metabolism distinguishes the action of peroxisome proliferator-activated receptor delta from Peroxisome proliferator-activated receptor gamma in the ob/ob mouse. Genome Med 2009, 1:115-115. 10.1186/gm115, 2808731, 19968882.
42. Roberts LD, Murray AJ, Menassa D, Ashmore T, Nicholls AW, Griffin JL. The contrasting roles of PPARδ and PPARγ in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue. Genome Biol 2011, 12:R75-R75. 10.1186/gb-2011-12-8-r75, 3245615, 21843327.
43. Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008, 57:332-339.
44. Gurung IS, Medina-Gomez G, Kis A, Baker M, Velagapudi V, Neogi SG, Campbell M, Rodriguez-Cuenca S, Lelliott C, McFarlane I, Oresic M, Grace AA, Vidal-Puig A, Huang CL. Deletion of the metabolic transcriptional coactivator PGC1β induces cardiac arrhythmia. Cardiovasc Res 2011, 92:29-38. 10.1093/cvr/cvr155, 21632884.
45. Lengqvist J, Mata De Urquiza A, Bergman AC, Willson TM, Sjovall J, Perlmann T, Griffiths WJ. Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid × receptor alpha ligand-binding domain. Mol Cell Proteomics 2004, 3:692-703. 10.1074/mcp.M400003-MCP200, 15073272.
46. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid × receptor heterodimers. Proc Natl Acad Sci USA 1993, 90:2160-2164. 10.1073/pnas.90.6.2160, 46045, 8384714.
47. Na H-K, Surh Y-J. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol 2003, 66:1381-1391. 10.1016/S0006-2952(03)00488-X, 14555212.
48. Hoggatt J, Pelus LM. Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking. Leukemia 2010, 24:1993-2002. 10.1038/leu.2010.216, 3099594, 20882043.
49. Poudyal H, Panchal SK, Diwan V, Brown L. Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. Prog Lipid Res 2011, 50:372-387. 10.1016/j.plipres.2011.06.003, 21762726.
50. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289-312. 10.1146/annurev.biochem.77.061307.091829, 18518822.
51. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995, 83:813-819. 10.1016/0092-8674(95)90194-9, 8521498.
52. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM, Dey SK. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999, 13:1561-1574. 10.1101/gad.13.12.1561, 316805, 10385625.
53. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995, 270:23975-23983. 10.1074/jbc.270.41.23975, 7592593.
54. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, Glass CK. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999, 400:378-382. 10.1038/22572, 10432118.
55. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93:229-240. 10.1016/S0092-8674(00)81574-3, 9568715.
56. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARgamma-mediated mechanisms in Alzheimer's disease models. PLoS One 6:e15816. 3016440, 21246057.
57. Kim YG, Lou AC, Saghatelian A. A metabolomics strategy for detecting protein-metabolite interactions to identify natural nuclear receptor ligands. Mol Biosyst 2011, 7:1046-1049. 10.1039/c0mb00324g, 21283866.
58. Masoodi M, Eiden M, Koulman A, Spaner D, Volmer DA. Comprehensive lipidomics analysis of bioactive lipids in complex regulatory networks. Anal Chem 2010, 82:8176-8185. 10.1021/ac1015563, 20828216.
59. Cohen G, Riahi Y, Shamni O, Guichardant M, Chatgilialoglu C, Ferreri C, Kaiser N, Sasson S. Role of lipid peroxidation and PPAR-δ in amplifying glucose-stimulated insulin secretion. Diabetes 2011, 60:2830-2842. 10.2337/db11-0347, 21896929.
60. Roberts RA, James NH, Hasmall SC, Holden PR, Lambe K, Macdonald N, West D, Woodyatt NJ, Whitcome D. Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARalpha. Toxicol Lett 2000, 112-113:49-57.
61. Gonzalez FJ, Shah YM. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 2008, 246:2-8. 10.1016/j.tox.2007.09.030, 18006136.
62. Roberts RA. Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators. Ann N Y Acad Sci 1996, 804:588-611. 10.1111/j.1749-6632.1996.tb18647.x, 8993575.
63. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997, 18:2029-2033. 10.1093/carcin/18.11.2029, 9395198.
64. Bayly AC, French NJ, Dive C, Roberts RA. Non-genotoxic hepatocarcinogenesis in vitro: the FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis. J Cell Sci 1993, 104:307-315.
65. Delaney J, Hodson MP, Thakkar H, Connor SC, Sweatman BC, Kenny SP, McGill PJ, Holder JC, Hutton KA, Haselden JN, Waterfield CJ. Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation. Arch Toxicol 2004, 79:208-223.
66. Connor SC, Hodson MP, Ringeissen S, Sweatman BC, McGill PJ, Waterfield CJ, Haselden JN. Development of a multivariate statistical model to predict peroxisome proliferation in the rat, based on urinary 1 H-NMR spectral patterns. Biomarkers 2004, 9:364-385. 10.1080/13547500400006005, 15764299.
67. Pogribny IP, Tryndyak VP, Boureiko A, Melnyk S, Bagnyukova TV, Montgomery B, Rusyn I. Mechanisms of peroxisome proliferator-induced DNA hypomethylation in rat liver. Mut Res 2008, 644:17-23.
68. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999, 12:413-439. 10.1002/(SICI)1099-1492(199911)12:7<413::AID-NBM587>3.0.CO;2-U, 10654290.
69. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004, 44:239-267. 10.1146/annurev.pharmtox.44.101802.121851, 14744246.
70. Angermüller S, Islinger M, Völkl A. Peroxisomes and reactive oxygen species, a lasting challenge. Histochem Cell Biol 2009, 131:459-463. 10.1007/s00418-009-0563-7, 19224237.
71. Reddy JK, Hashimoto T. Peroxisomal β-oxidation and peroxisome proliferator-activated receptor α: an adaptive metabolic system. Annu Rev Nutr 2001, 21:193-230. 10.1146/annurev.nutr.21.1.193, 11375435.
72. Lake BG, Gray TJB, Stubberfield CR, Beamand JA, Gangolli SD. Induction of lauric acid hydroxylation and maintenance of cytochrome P-450 content by clofibrate in primary cultures of rat hepatocytes. Life Sci 1983, 33:249-254. 10.1016/0024-3205(83)90383-1, 6865658.
73. Giera DD, van Lier RBL. A convenient method for the determination of hepatic lauric acid ω-oxidation based on solvent partition. Fundam Appl Toxicol 1991, 16:348-355. 10.1016/0272-0590(91)90119-O, 2055365.
74. Tang Z, Guengerich FP. Dansylation of unactivated alcohols for improved mass spectral sensitivity and application to analysis of cytochrome P450 oxidation products in tissue extracts. Anal Chem 2010, 82:7706-7712. 10.1021/ac1015497, 2941762, 20795636.